Biopharma VC funding delivered its strongest opening half in four years. Yet the headline figure hides a widening split. Mature, de-risked companies are attracting capital, while the seed-stage startups that supply the sector’s long-term pipeline are not. Data compiled by BioPharma Dive show that at least 68 biotech companies raised more than $9.1 billion between January and June 2026. That is the highest first-half total since the start of 2022 among companies backed by the 26 venture firms the publication tracks.
Biopharma VC funding returns to 2022 levels
The rebound came from a small number of very large cheques rather than a broad reopening of the market. About 76% of the money raised in the first half arrived through megarounds worth $100 million or more, according to BioPharma Dive.
Ben Zercher, senior biotech and pharma analyst at PitchBook, said venture capital had continued to perform strongly. He pointed to two pressures it had absorbed: the threat of a United States crackdown on investment in Chinese drug assets, and continuing turnover at the Food and Drug Administration.
That resilience is notable, because policy conditions were not obviously supportive. Cuts to National Institutes of Health research budgets, tighter scrutiny of cross-border licensing and regulatory uncertainty might all have been expected to cool investor appetite. Instead, investment held up. A functioning exit market helped.
Megarounds dominated the funding league table
Biopharma VC funding in the first half was heavily concentrated at the top. One financing alone was equivalent to close to a quarter of the tracked half-year total.
Isomorphic Labs announced a $2.1 billion Series B on 12 May. The Alphabet-backed company is headquartered in London. Thrive Capital led the round, with existing backers Alphabet and GV taking part alongside new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. PitchBook has described it as the second largest biotech venture round on record, behind the $3 billion launch of Altos Labs in 2022. Founder and chief executive Sir Demis Hassabis, in the company’s announcement, called the round “a massive vote of confidence from a diverse group of top-tier international investors”. Isomorphic has yet to name a clinical candidate. The proceeds will scale its IsoDDE drug design engine and move therapeutic programmes towards the clinic.
Robert Stanislaro, Senior Managing Director at FTI Consulting, told BioSpace that megarounds of this kind pull the overall funding numbers upwards. Investors write early cheques, he said, where the science is unusually strong, the syndicate is high quality, or the path to a near-term catalyst is credible.
The next largest rounds were more conventional in shape. NewLimit raised $435 million in a Series C on 3 June; the California company works on epigenetic reprogramming. Beeline Medicines launched in April with $300 million, five immunology assets from Bristol Myers Squibb and backing from Bain Capital, then upsized its Series A to $426.3 million on 30 June. Parabilis Medicines banked $305 million in a rare Series F in January. Corxel Pharmaceuticals followed with $287 million in a Series D1 later that month, to advance its oral GLP-1 receptor agonist CX11.
The early-stage biopharma VC funding gap keeps widening
The composition of those rounds is what concerns investors and advisers most. Roughly two-thirds of first-half rounds, 42 of them, went to companies that already had a drug candidate in human testing.
Ashwin Singhania, a principal in Ernst & Young’s life sciences practice, asked “where is that next wave of early innovation going to come from”. He linked the risk to reduced NIH support, with consequences that may take a decade to surface.
Mike Nelson, a partner at law firm Cooley, told BioSpace that capital remains concentrated in later-stage assets with near-term clinical catalysts. Seed and Series A activity, he said, is on pace for its lowest annual count since before the pandemic. Zercher has also cautioned that round labels can mislead. Many Series A and B megarounds, he noted, come from companies founded five or more years ago with relatively mature operations.
Stanislaro put the shift plainly: “Investors are recalibrating their measures of confidence, not expanding their tolerance for risk.” Doreen Levine, a partner at Ernst & Young, made a similar point to BioPharma Dive. Venture firms have both the liquidity and the interest to invest, she said, but they are being highly judicious.
Where the money went by therapeutic area and modality
Therapeutic preferences reinforced that caution. Immune and cancer-focused developers accounted for more than 40% of first-half rounds. Biologics developers and small molecule developers each raised more than $2 billion, and other modalities trailed well behind. Sharad Chandra Vinayak of DelveInsight told BioSpace that investors favoured platform technologies over single-asset companies.
Cell and gene therapy remained the clear laggard. Companies in the field are on pace to raise about $2 billion across 2026, broadly in line with most years since 2022. Zercher attributed the weakness to three factors: disappointing commercial performance from approved products such as Casgevy, safety signals in some trials, and heightened regulatory scrutiny.
Exit markets reopened
Improved liquidity underpinned much of the biopharma VC funding confidence. BioPharma Dive counted 13 biotech listings raising a combined $4.5 billion by mid-July. The median haul was close to $302 million, unusually high by historical standards. BioSpace applies a broader screen and tallied 18 biotech IPOs by early July, against eight in the whole of 2025.
Parabilis Medicines, which took the January Series F, returned in June with a $670 million IPO. Trade coverage described it as the largest IPO on record for a venture-backed biotechnology company, ahead of the $625 million priced in April by Kailera Therapeutics, whose final gross proceeds reached $718.8 million once underwriters exercised their overallotment option in full.
Acquisitions told a similar story, and they matter to venture investors because they return capital to funds. BioPharma Dive recorded 38 takeouts by mid-July, the fastest pace in at least seven years. Almost two-thirds were valued at $1 billion or more, and four exceeded $10 billion. Life Science Daily News reported in June that first-half dealmaking had already passed the full-year 2025 total, at approximately $134 billion.
UK biotech posts a five-year high
For British companies, the half was transformative on paper. The BIA’s first-quarter report showed UK biotech equity financing reached £552 million between January and March. Venture capital accounted for £516 million of that, a 17% increase on the previous quarter.
BioIndustry Association figures show the second quarter then produced £2.11 billion in total equity financing, including a record £2.05 billion in venture capital. Isomorphic accounted for £1.6 billion of that quarterly figure. Strip it out and UK companies still raised £498 million in venture capital, close to double the £279 million recorded a year earlier. The UK took 61% of Europe’s £3.3 billion venture total for the quarter.
UK biopharma VC funding also broadened at the base. Eight seed deals completed, averaging £6.4 million. Series A companies raised approximately £190 million, while Series B and later companies raised approximately £225 million. Chris Molloy, chief executive of the BIA, called it “the strongest single quarter for UK life sciences venture funding” in five years.
Institutional support firmed too. Nest committed £1 billion to UK scale-ups through the Schroders Capital UK Innovation LTAF. The British Business Bank invested £25 million in Alchemab, its largest direct life sciences commitment to date.
Public markets remain the weak point. Follow-on financing rose to £58 million in the second quarter, up from £36 million in the first. However, no UK biotech completed an IPO during the half. There was no follow-on activity from UK companies listed on Nasdaq either.
Why the totals differ between trackers
Anyone comparing these reports should treat headline numbers with care, because methodologies diverge sharply. BioPharma Dive screens for rounds involving at least one of 26 named venture firms, producing a deliberately narrow but consistent series. The BIA counts all equity financing raised by UK-headquartered biotech companies.
PitchBook applies a narrower European biotech vertical, which does not appear to capture the Isomorphic round. On that basis, about €800 million had been invested across Europe by mid-July. The figure represents more than three-quarters of the 2025 total, and puts Europe on course to beat its 2018 record of €1.2 billion. Europe took 20.5% of global biotech funding on the same measure, its highest share since 2018. United States fundraising, however, still ran at roughly three times the European level.
Biopharma VC funding: what to watch in H2 2026
Three questions will shape biopharma VC funding through the rest of the year.
The first concerns early-stage company formation. Will it recover, or will company creation keep migrating towards ready-made assets in-licensed from China and elsewhere? BioPharma Dive reports that the flow of funding to such companies has raised concerns over national security and market competition.
The second concerns the IPO window. It needs to stay open long enough to return capital to venture funds and finance the next cycle of company creation.
The third matters most in Britain. UK public markets have yet to follow private capital, and a domestic listing route remains absent despite record private financing.
For now, the picture is one of concentration rather than exuberance. Biopharma VC funding is flowing freely. It is simply flowing to fewer companies, later in their development, and on terms that reward evidence over ambition.
